Form 8-K - Current report:
SEC Accession No. 0001558370-25-007065
Filing Date
2025-05-09
Accepted
2025-05-09 07:13:06
Documents
15
Period of Report
2025-05-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K qure-20250509x8k.htm   iXBRL 8-K 36619
2 EX-99.1 qure-20250509xex99d1.htm EX-99.1 144466
3 GRAPHIC qure-20250509xex99d1001.jpg GRAPHIC 5856
  Complete submission text file 0001558370-25-007065.txt   320440

Data Files

Seq Description Document Type Size
4 EX-101.SCH qure-20250509.xsd EX-101.SCH 3263
5 EX-101.LAB qure-20250509_lab.xml EX-101.LAB 15215
6 EX-101.PRE qure-20250509_pre.xml EX-101.PRE 9965
17 EXTRACTED XBRL INSTANCE DOCUMENT qure-20250509x8k_htm.xml XML 4599
Mailing Address PAASHEUVELWEG 25A AMSTERDAM P7 1105 BP
Business Address PAASHEUVELWEG 25A AMSTERDAM P7 1105 BP 1-339-970-7000
uniQure N.V. (Filer) CIK: 0001590560 (see all company filings)

EIN.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36294 | Film No.: 25928367
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)